• AbClon signed an amended agreement with Yuhan on Oct. 30, 2026, concluding their TIGIT-targeted antibody drug development collaboration.
• The settlement totals 1 billion won, equivalent to at least 10% of the previous fiscal year's revenue.
• All rights to research results under the original 2016 agreement, including drug candidate technology, transfer to Yuhan.
• The agreement leaves no additional performance obligations or contingent liabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbClon Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030900497), on October 30, 2026, and is solely responsible for the information contained therein.